You don't have an agenda my arse. For the record, Ryoncil has killed no one, ever. It really is a massive stat when you drill down into it. You know (and have been told) that adverse reaction reports must include any outcome that could possibly be related to the drug, whether likely or not. The safety data for Ryoncil is and has always been impeccable. Children who have failed all available therapies for aGVHD are some of the sickest beings on the planet and rather than probable death there are better than 2 out of 3 odds of survival (and that is likely to improve as more is learned). The presentation demonstrates that Ryoncil will save insurers money as a result. I guess that was your outperform strategy, and you had another for underperform.
MSB Price at posting:
$2.52 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)